Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
18.13
+0.05 (0.28%)
Mar 4, 2026, 10:19 AM EST - Market open
Takeda Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 33,287 | 108,143 | 144,197 | 317,038 | 230,166 | 376,171 |
Depreciation & Amortization | 900,949 | 867,925 | 878,019 | 728,794 | 637,666 | 585,123 |
Stock-Based Compensation | 71,189 | 72,867 | 70,871 | 60,672 | 43,374 | 37,663 |
Other Adjustments | 234,131 | 238,207 | 99,201 | 94,356 | 261,020 | -28,006 |
Change in Receivables | 37,106 | -58,959 | 15,104 | 75,127 | 127,294 | -9,316 |
Changes in Inventories | -25,786 | -34,973 | -115,743 | -79,155 | -46,148 | 25,978 |
Changes in Accounts Payable | 18,719 | -7,118 | -9,895 | -84,804 | 125,157 | 36,620 |
Changes in Other Operating Activities | -140,964 | -128,911 | -365,410 | -134,871 | -255,422 | -13,302 |
Operating Cash Flow | 1,199,566 | 1,057,182 | 716,344 | 977,156 | 1,123,105 | 1,010,931 |
Operating Cash Flow Growth | 36.89% | 47.58% | -26.69% | -13.00% | 11.10% | 50.94% |
Capital Expenditures | -181,889 | -200,795 | -175,420 | -140,657 | -123,252 | -111,206 |
Sale of Property, Plant & Equipment | 9,618 | 78 | 8,606 | 962 | 1,815 | 46,453 |
Purchases of Intangible Assets | -95,608 | -178,830 | -305,310 | -493,032 | -62,785 | -125,262 |
Purchases of Investments | -70,114 | -98,540 | -6,766 | -10,151 | -8,341 | -12,596 |
Proceeds from Sale of Investments | 10,680 | 87,133 | 8,021 | 22,254 | 16,921 | 74,604 |
Payments for Business Acquisitions | - | - | - | - | -49,672 | - |
Proceeds from Business Divestments | 41,871 | 20,556 | 19,959 | 7,958 | 28,196 | 530,388 |
Other Investing Activities | 15,352 | 3,337 | -12,951 | 5,564 | -1,008 | -8,851 |
Investing Cash Flow | -216,562 | -367,060 | -463,862 | -607,102 | -198,125 | 393,530 |
Net Short-Term Debt Issued (Repaid) | 174,955 | 27,490 | 277,000 | 40,000 | -2 | -149,043 |
Long-Term Debt Issued | 586,060 | 1,024,460 | 100,000 | 75,000 | 249,334 | 1,179,515 |
Long-Term Debt Repaid | -1,162,456 | -1,321,090 | -320,901 | -356,670 | -810,115 | -1,651,706 |
Net Long-Term Debt Issued (Repaid) | -576,396 | -296,630 | -220,901 | -281,670 | -560,781 | -472,191 |
Repurchase of Common Stock | -152,372 | -51,860 | -2,326 | -26,929 | -77,531 | -2,141 |
Net Common Stock Issued (Repurchased) | -152,372 | -51,860 | -2,326 | -26,929 | -77,531 | -2,141 |
Common Dividends Paid | -309,271 | -302,498 | -287,188 | -279,416 | -283,665 | -283,357 |
Other Financing Activities | -180,102 | -127,925 | -121,000 | -161,134 | -148,286 | -181,622 |
Financing Cash Flow | -1,184,642 | -751,425 | -354,416 | -709,148 | -1,070,265 | -1,088,354 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 24,108 | -11,385 | 26,204 | 22,929 | 28,758 | 12,501 |
Net Cash Flow | -201,638 | -61,303 | -101,934 | -339,094 | -145,285 | 316,107 |
Free Cash Flow | 1,017,677 | 856,387 | 540,924 | 836,499 | 999,853 | 899,725 |
Free Cash Flow Growth | 18.83% | 58.32% | -35.34% | -16.34% | 11.13% | 65.80% |
FCF Margin | 22.53% | 18.69% | 12.69% | 20.77% | 28.01% | 28.14% |
Free Cash Flow Per Share | - | - | - | 266.42 | 316.98 | 285.89 |
Levered Free Cash Flow | 406,229 | 334,816 | 411,717 | 364,654 | 7,277 | 277,984 |
Unlevered Free Cash Flow | 1,259,940 | 969,693 | -241,963 | 853,762 | 909,125 | 1,018,665 |
Updated Oct 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.